[go: up one dir, main page]

MX2011007754A - Composicion farmaceutica finamente pulverizada. - Google Patents

Composicion farmaceutica finamente pulverizada.

Info

Publication number
MX2011007754A
MX2011007754A MX2011007754A MX2011007754A MX2011007754A MX 2011007754 A MX2011007754 A MX 2011007754A MX 2011007754 A MX2011007754 A MX 2011007754A MX 2011007754 A MX2011007754 A MX 2011007754A MX 2011007754 A MX2011007754 A MX 2011007754A
Authority
MX
Mexico
Prior art keywords
finely pulverized
pharmaceutical composition
composition
poorly soluble
medicinal substance
Prior art date
Application number
MX2011007754A
Other languages
English (en)
Inventor
Shigeru Chikase
Dai Kawada
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of MX2011007754A publication Critical patent/MX2011007754A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición que contiene una sustancia medicinal pobremente soluble y que tiene absorción oral mejorada y un método para producir la composición. Se describe específicamente una composición finamente pulverizada que contiene una sustancia medicinal pobremente soluble tal como 22ß-metoxiolean-l2-eno--3ß,2 4(4ß)-diol y un agente tensioactivo hidrofílico. También se describe específicamente un método para producir una composición finamente pulverizada, que se caracteriza porque una sustancia medicinal poco soluble y una gente tensioactivo hidrofílico se dispersan primero en un solvente y luego se pulverizan por un homogeneizador de alta presión.
MX2011007754A 2009-01-30 2010-01-29 Composicion farmaceutica finamente pulverizada. MX2011007754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009019771 2009-01-30
PCT/JP2010/051262 WO2010087447A1 (ja) 2009-01-30 2010-01-29 微粉砕医薬組成物

Publications (1)

Publication Number Publication Date
MX2011007754A true MX2011007754A (es) 2011-08-12

Family

ID=42395702

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007754A MX2011007754A (es) 2009-01-30 2010-01-29 Composicion farmaceutica finamente pulverizada.

Country Status (12)

Country Link
US (1) US20110294901A1 (es)
EP (1) EP2392354A4 (es)
JP (1) JPWO2010087447A1 (es)
KR (1) KR20110117145A (es)
CN (1) CN102365098A (es)
AU (1) AU2010208880A1 (es)
BR (1) BRPI1007557A2 (es)
CA (1) CA2751236A1 (es)
MX (1) MX2011007754A (es)
RU (1) RU2011135958A (es)
SG (1) SG173158A1 (es)
WO (1) WO2010087447A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108567803B (zh) * 2018-06-29 2021-03-02 江西济民可信药业有限公司 一种金水宝金胶囊的制备方法
EP4588473A1 (en) * 2022-09-12 2025-07-23 PTC Therapeutics, Inc. Granules for suspension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU690687B2 (en) * 1994-09-12 1998-04-30 Ecolab Inc. Rinse aid for plasticware
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
WO1997003088A1 (fr) * 1995-07-07 1997-01-30 Meiji Seika Kabushiki Kaisha Derives triterpenes et medicament pour les maladies du foie
JP3384967B2 (ja) * 1997-08-07 2003-03-10 花王株式会社 脂肪酸類からの飽和脂肪酸の低減方法
KR100786927B1 (ko) * 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
EP1587499A1 (en) * 2003-01-31 2005-10-26 Elan Pharma International Limited Nanoparticulate topiramate formulations
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
WO2008123093A1 (ja) * 2007-03-20 2008-10-16 Meiji Seika Kaisha, Ltd. 鉄過剰症の予防または治療剤

Also Published As

Publication number Publication date
SG173158A1 (en) 2011-08-29
CN102365098A (zh) 2012-02-29
KR20110117145A (ko) 2011-10-26
BRPI1007557A2 (pt) 2016-02-16
EP2392354A4 (en) 2012-08-08
EP2392354A1 (en) 2011-12-07
AU2010208880A1 (en) 2011-08-18
US20110294901A1 (en) 2011-12-01
WO2010087447A1 (ja) 2010-08-05
RU2011135958A (ru) 2013-03-10
CA2751236A1 (en) 2010-08-05
JPWO2010087447A1 (ja) 2012-08-02

Similar Documents

Publication Publication Date Title
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
WO2010072958A3 (fr) Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2007135461A3 (en) Pharmaceutical compositions comprising implitapide and methods of using same
WO2010097243A3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
MX2009003065A (es) Formulacion efervescente de ibuprofeno con alto indice de disolucion y proceso para su preparacion.
PL2217219T3 (pl) Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną
WO2010056039A3 (en) Oral pharmaceutical formulation of pelubiprofen with improved dissolution rate and stability
WO2007084221A9 (en) Methods and apparatus for identifying subject matter in view data
MX2015000023A (es) Profármacos novedosos de rebamipida, metodo preparación y su uso.
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
WO2011081373A3 (en) Method for preparing highly pure anhydrous crystalline docetaxel
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
MX2011007754A (es) Composicion farmaceutica finamente pulverizada.
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
WO2009120933A3 (en) Pharmaceutical solutions and method for solubilizing therapeutic agents
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
BR112015015202A2 (pt) composição
WO2009120844A3 (en) Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
WO2011031099A3 (en) Ursodeoxycholic acid-synthetic hydrotalcite-eudragit hybrid, pharmaceutical composition containing the same and method for preparing the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal